Nevertheless, a preclinical study conducted in 2013 indicated that dasatinib can impair growth, proliferation and induce morphological differentiation in only primary melanoma cells attributed to its ability to suppress activated ERK nuclear translocation (Table 1) [61]. Here, EPHB2 is linked to melanoma.